Teacher Retirement System of Texas Purchases Shares of 4,905 TransMedics Group, Inc. (NASDAQ:TMDX)

Teacher Retirement System of Texas acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,905 shares of the company's stock, valued at approximately $330,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Clear Creek Financial Management LLC raised its holdings in shares of TransMedics Group by 5.8% in the first quarter. Clear Creek Financial Management LLC now owns 5,963 shares of the company's stock worth $401,000 after buying an additional 325 shares during the period. Vontobel Holding Ltd. bought a new stake in TransMedics Group during the 1st quarter valued at $291,000. Peregrine Capital Management LLC boosted its position in TransMedics Group by 3.4% during the 1st quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company's stock valued at $4,601,000 after acquiring an additional 2,250 shares in the last quarter. Taylor Frigon Capital Management LLC boosted its position in TransMedics Group by 28.1% during the 1st quarter. Taylor Frigon Capital Management LLC now owns 31,540 shares of the company's stock valued at $2,122,000 after acquiring an additional 6,922 shares in the last quarter. Finally, New York State Teachers Retirement System boosted its position in TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock valued at $1,477,000 after acquiring an additional 14,200 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Trading Down 2.3%

TMDX traded down $2.64 during trading hours on Friday, reaching $109.88. The company's stock had a trading volume of 789,501 shares, compared to its average volume of 1,384,062. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a market cap of $3.72 billion, a PE ratio of 80.79 and a beta of 2.06. The business's 50-day moving average is $127.13 and its 200-day moving average is $92.46. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The firm's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 earnings per share. As a group, equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director David Weill sold 732 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director directly owned 12,134 shares of the company's stock, valued at $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,418 shares of company stock worth $1,512,613. Corporate insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

TMDX has been the subject of a number of research analyst reports. Canaccord Genuity Group raised their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Piper Sandler restated an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Oppenheimer raised their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $129.88.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.